SCHEMBL20208720

SCHEMBL20208720

CC(C)C(=O)Nc1nc(OCCC#N)c2ncn(C)c2n1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 6/20 0.45
CDK5R1 Q15078 6/20 0.45
ADORA1 P30542 2/20 0.36
ADORA2A P29274 1/20 0.36
PRKD3 O94806 1/20 0.35
MAPK8 P45983 1/20 0.35
MAPK9 P45984 1/20 0.35
JAK2 O60674 2/20 0.35
JAK1 P23458 2/20 0.35
TYK2 P29597 2/20 0.35
JAK3 P52333 2/20 0.35
CDK1 P06493 2/20 0.34
CCNB2 O95067 1/20 0.33
CCNB1 P14635 1/20 0.33
CCNB3 Q8WWL7 1/20 0.33
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20208862 0.88 CDK5 (0.44) CDK5CDK5R1ADORA1ADORA2APRKD3
SCHEMBL25768308 0.88 CDK5 (0.58) CDK5CDK5R1CDK1CCNB2CCNB1
SCHEMBL20806161 0.87 CDK5 (0.43) CDK5CDK5R1ADORA1ADORA2APRKD3
SCHEMBL22020964 0.84 CDK5 (0.41) CDK5CDK5R1ADORA1ADORA2APRKD3
SCHEMBL19660229 0.81 HTT (0.40) CDK5CDK5R1ADORA1ADORA2AMAPK8
SCHEMBL21347453 0.80 MAPK8 (0.40) ADORA1ADORA2AMAPK8MAPK9
SCHEMBL20208722 0.78 ADORA1 (0.37) CDK5CDK5R1ADORA1ADORA2APRKD3
SCHEMBL19660601 0.78 CDK5 (0.33) CDK5CDK5R1CDK1
SCHEMBL26734570 0.75 CDK5 (0.47) CDK5CDK5R1ADORA1ADORA2APRKD3
SCHEMBL22399470 0.74 CDK5 (0.47) CDK5CDK5R1ADORA1CDK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348524-A1 TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION WAVE LIFE SCIENCES LTD. (SG) 2023-11-02 US disclosed
US-20230348524-A1 TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION WAVE LIFE SCIENCES LTD. (SG) 2023-11-02 US disclosed
WO-2023154528-A1 STEREOSELECTIVE TECHNOLOGIES FOR CHIRAL COMPOUNDS WAVE LIFE SCIENCES LTD. (SG) 2023-08-17 WO disclosed
WO-2020191252-A1 TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION WAVE LIFE SCIENCES LTD. (SG) 2020-09-24 WO disclosed
WO-2019055951-A1 TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION WAVE LIFE SCIENCES LTD. (SG) 2019-03-21 WO disclosed
WO-2019032607-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2019-02-14 WO disclosed
WO-2019032612-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2019-02-14 WO disclosed
WO-2018098264-A1 COMPOSITIONS AND METHODS FOR PHOSPHORAMIDITE AND OLIGONUCLEOTIDE SYNTHESIS WAVE LIFE SCIENCES LTD. (SG) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348524-A1 TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION POLRMT, DCLRE1B, RNGTT CDK5 2352/4885CDK5R1 3009/4885ADORA1 410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.